CM
CM Management Portfolio holdings
AUM
$110M
This Quarter Return
+25.59%
1 Year Return
+9.76%
3 Year Return
+99.54%
5 Year Return
–
10 Year Return
–
AUM
$124M
AUM Growth
+$124M
(+32%)
Cap. Flow
+$8.38M
Cap. Flow
% of AUM
6.73%
Top 10 Holdings %
Top 10 Hldgs %
42.82%
Holding
77
New
12
Increased
23
Reduced
17
Closed
5
Top Buys
| 1 |
Royalty Pharma
RPRX
|
$3.51M |
| 2 |
inTEST
INTT
|
$1.63M |
| 3 |
Organon & Co
OGN
|
$1.59M |
| 4 |
Newell Brands
NWL
|
$1.52M |
| 5 |
Pfizer
PFE
|
$1.44M |
Top Sells
| 1 |
National Healthcare
NHC
|
$4.16M |
| 2 |
SWN
Southwestern Energy Company
SWN
|
$2.1M |
| 3 |
Talos Energy
TALO
|
$1.85M |
| 4 |
DURECT Corp
DRRX
|
$1.31M |
| 5 |
Fidelity National Financial
FNF
|
$1.28M |
Sector Composition
| 1 | Healthcare | 44.16% |
| 2 | Financials | 8.39% |
| 3 | Technology | 8.19% |
| 4 | Industrials | 7.86% |
| 5 | Materials | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Vital Energy
VTLE
$682M
| $682K | 0.55% |
+15,000
| New | +$682K |
|
|
RVNC
52
DELISTED
Revance Therapeutics, Inc.
RVNC
| $659K | 0.53% |
+75,000
| New | +$659K |
|
53
Heron Therapeutics
HRTX
$204M
| $553K | 0.44% |
325,000
-125,000
| -28% | -$213K |
|
54
Nektar Therapeutics
NKTR
$543M
| $531K | 0.43% |
939,847
+139,847
| +17% | +$79K |
|
|
SFE
55
DELISTED
Safeguard Scientifics, Inc.
SFE
| $527K | 0.42% |
671,671
| – | – |
|
56
Smith Micro Software
SMSI
$15.2M
| $496K | 0.4% |
600,000
+300,000
| +100% | +$248K |
|
57
Cartesian Therapeutics
RNAC
$267M
| $483K | 0.39% |
700,000
| – | – |
|
58
BioCardia
BCDA
$11.8M
| $465K | 0.37% |
700,000
+100,000
| +17% | +$66.4K |
|
59
Cytosorbents Corp
CTSO
$61.5M
| $461K | 0.37% |
415,000
-35,000
| -8% | -$38.9K |
|
60
Femasys
FEMY
$12M
| $439K | 0.35% |
450,000
+325,000
| +260% | +$317K |
|
61
Elicio Therapeutics
ELTX
$169M
| $417K | 0.34% |
50,000
-15,000
| -23% | -$125K |
|
62
Assertio
ASRT
$78M
| $369K | 0.3% |
345,000
+177,360
| +106% | +$190K |
|
63
Lantern Pharma
LTRN
$46.3M
| $342K | 0.28% |
80,000
+5,000
| +7% | +$21.4K |
|
64
Curis
CRIS
$21.5M
| $319K | 0.26% |
25,000
-2,500
| -9% | -$31.9K |
|
|
KRON
65
DELISTED
Kronos Bio
KRON
| $313K | 0.25% |
250,000
| – | – |
|
66
Cadence Bank
CADE
$6.97B
| $296K | 0.24% |
10,000
| – | – |
|
67
Gain Therapeutics
GANX
$69M
| $294K | 0.24% |
90,000
| – | – |
|
68
Edesa Biotech
EDSA
$17.2M
| $283K | 0.23% |
62,000
-355,602
| -85% | +$10.7K |
|
69
Eledon Pharmaceuticals
ELDN
$155M
| $252K | 0.2% |
140,000
-94,803
| -40% | -$171K |
|
70
Compass Therapeutics
CMPX
$466M
| $195K | 0.16% |
+125,000
| New | +$195K |
|
71
NeueHealth
NEUE
$60.6M
| $137K | 0.11% |
18,000
-7,715
| -30% | -$58.9K |
|
|
PVLA
72
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $137K | 0.11% |
750,000
+100,600
| +15% | +$18.3K |
|
|
73
DURECT Corp
DRRX
$60.2M
| – | – |
-525,000
| Closed | -$1.31M |
|
74
Bristow Group
VTOL
$1.07B
| – | – |
-35,000
| Closed | -$986K |
|
75
World Kinect Corp
WKC
$1.52B
| – | – |
-30,000
| Closed | -$673K |
|